The recently completed phase III MIRASOL study, indicating that treatment with "mirvetuximab soravtansine-gynx, compared with chemotherapy, was associated with significant benefits in terms of progression-free survival (PFS), objective response, and overall survival (OS)" in ovarian cancer patients. Platinum-resistant ovarian cancer has few targeted treatments available, thus "mirvetuximab soravtansine-gynx appears to be capable of inducing responses and improving survival.."
To read more about this study, click here.
Source mentioned:
Moore KN. Angelergues A, Konecny GE, et al. for Gynecologic Oncology Group Partners and the European Network of Gynaecological Oncological Trial Groups. Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer. N Engl J Med 2023;389:2162-2174.
No comments:
Post a Comment